RU2005135440A - Антагонисты рецептора cgrp - Google Patents
Антагонисты рецептора cgrp Download PDFInfo
- Publication number
- RU2005135440A RU2005135440A RU2005135440/04A RU2005135440A RU2005135440A RU 2005135440 A RU2005135440 A RU 2005135440A RU 2005135440/04 A RU2005135440/04 A RU 2005135440/04A RU 2005135440 A RU2005135440 A RU 2005135440A RU 2005135440 A RU2005135440 A RU 2005135440A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- heteroaryl
- unsubstituted
- substituted
- independently selected
- Prior art date
Links
- SVSUWNAKQHBGJH-LJSVPSOQSA-N CC1(C2)C3[C@@H]2CCC1C3 Chemical compound CC1(C2)C3[C@@H]2CCC1C3 SVSUWNAKQHBGJH-LJSVPSOQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (5)
1. Соединение формулы I
где R1 выбран из
Н, С1-С6-алкила, С3-С6-циклоалкила и гетероцикла, незамещенного или замещенного одним или несколькими заместителями, независимо друг от друга выбранными из
С1-С6-алкила, С3-С6-циклоалкила, фенила, гетероарила, гетероцикла, (F)pС1-С3-алкила, галогена, OR4, O(CH2)sOR4, CO2R4, CN, NR10R11, O(CO)R4,
где указанный фенил, указанный гетероарил и указанный гетероцикл каждый независимо друг от друга является незамещенным или замещен 1-5 заместителями, где заместители независимо друг от друга выбраны из R4,
где указанный гетероарил выбран из имидазола, изоксазола, оксазола, пиразина, пиразола, пиридазина, пиридина, пиримидина и тиазола;
где указанный гетероцикл выбран из азетидина, диоксана, диоксолана, морфолина, оксетана, пиперазина, пиперидина, пирролидина, тетрагидрофурана и тетрагидропирана;
арил или гетероарил выбраны из фенила, имидазола, изоксазола, оксазола, пиразина, пиразола, пиридазина, пиридина, пиримидина и тиазола,
где указанный арил и указанный гетероарил каждый независимо друг от друга является незамещенным или замещен одним или несколькими заместителями, независимо друг от друга выбранными из С1-С6-алкила, С3-С6-циклоалкила, (F)pС1-С3-алкила, галогена, OR4, CO2R4, (CO)NR10R11, SO2NR10R11, N(R10)SO2R11, S(O)mR4, CN, NR10R11 и O(CO)R4;
R2 выбран из
Н, С0-С6-алкила, С3-С6-циклоалкила и гетероцикла, незамещенного или замещенного одним или несколькими заместителями, независимо друг от друга выбранными из:
С1-С6-алкила, С3-С6-циклоалкила, фенила, гетероарила, гетероцикла, (F)pС1-С3-алкила, галогена, OR4, O(CH2)sOR4, CO2R4, CN, NR10R11 и O(CO)R4;
где указанный фенил, указанный гетероарил и указанный гетероцикл каждый независимо друг от друга является незамещенным или замещен 1-5 заместителями, независимо друг от друга выбранными из R4,
где указанный гетероарил выбран из: бензимидазола, бензотиофена, фурана, имидазола, индола, изоксазола, оксазола, пиразина, пиразола, пиридазина, пиридина, пиримидина, пиррола, тиазола, тиофена и триазола;
где указанный гетероцикл выбран из: азетидина, имидазолидина, имидазолина, изоксазолина, изоксазолидина, морфолина, оксазолина, оксазолидина, оксетана, пиразолидина, пиразолина, пирролина, тетрагидрофурана, тетрагидропирана, тиазолина и тиазолидина;
арил или гетероарил выбраны из: фенила, бензимидазола, бензотиофена, фурана, имидазола, индола, изоксазола, оксазола, пиразина, пиразола, пиридазина, пиридина, пиримидина, пиррола, тиазола, тиофена и триазола;
где указанный арил и указанный гетероарил каждый независимо друг от друга является незамещенным или замещен одним или несколькими заместителями, независимо друг от друга выбранными из: С1-С6-алкила, С3-С6-циклоалкила, (F)pС1-С3-алкила, галогена, OR4, CO2R4, (CO)NR10R11, SO2NR10R11, N(R10)SO2R11, S(O)mR4, CN, NR10R11 и O(CO)R4;
R10 и R11 независимо друг от друга выбраны из: Н, С1-С6-алкила, (F)pС1-С6-алкила, С3-С6-циклоалкила, арила, гетероарила и бензила, незамещенного или замещенного галогеном, гидрокси или С1-С6-алкокси, где R10 и R11 могут быть объединены вместе с образованием цикла, выбранного из азетидинила, пирролидинила, пиперидинила, пиперазинила и морфолинила, который является незамещенным или замещен 1-5 заместителями, где заместители независимо друг от друга выбраны из R4;
R4 независимо друг от друга выбраны из Н, С1-С6-алкила, (F)pС1-С6-алкила, С3-С6-циклоалкила, арила, гетероарила и фенила, незамещенного или замещенного гидрокси или С1-С6-алкокси;
R3 независимо друг от друга выбраны из: Н, замещенного или незамещенного С1-С3-алкила, CN или CO2R4;
р принимает значения от 0 до 2q+1, для заместителей с q атомами углерода;
m принимает значения 0, 1 или 2;
s принимает значения 1, 2 или 3;
и его фармацевтически приемлемые соли и индивидуальные диастереомеры.
2. Соединение формулы
где R1 выбран из
С1-С6-алкила, незамещенного или замещенного одним или несколькими заместителями, независимо друг от друга выбранными из: С1-С6-алкила, С3-С6-циклоалкила, фенила, гетероарила, гетероцикла, (F)pС1-С3-алкила, галогена, OR4, O(CH2)sOR4, CO2R4, CN, NR10R11 и O(CO)R4,
R2 выбран из
арила, незамещенного или замещенного одним или несколькими заместителями, независимо друг от друга выбранными из С1-С6-алкила, С3-С6-циклоалкила, (F)pС1-С3-алкила, галогена, OR4, CO2R4, (CO)NR10R11, SO2NR10R11, N(R10)SO2R11, S(O)mR4, CN, NR10R11 и O(CO)R4;
R10 и R11 независимо друг от друга выбраны из: Н, С1-С6-алкила, (F)pС1-С6-алкила, С3-С6-циклоалкила, арила, гетероарила и бензила, незамещенного или замещенного галогеном, гидрокси или С1-С6-алкокси, где R10 и R11 могут быть объединены вместе с образованием цикла, выбранного из: азетидинила, пирролидинила, пиперидинила, пиперазинила и морфолинила, который является незамещенным или замещен 1-5 заместителями, где заместители независимо друг от друга выбраны из R4;
R4 независимо друг от друга выбраны из Н, С1-С6-алкила, (F)pС1-С6-алкила, С3-С6-циклоалкила, арила, гетероарила и фенила, незамещенного или замещенного гидрокси или С1-С6-алкокси;
р принимает значения от 0 до 2q+1, для заместителей с q атомами углерода;
m принимает значения 0, 1 или 2;
s принимает значения 1, 2 или 3;
и его фармацевтически приемлемые соли и индивидуальные диастереомеры.
4. Фармацевтическая композиция, которая содержит инертный носитель и соединение по п.1.
5. Применение соединения по п.1 для получения медикамента, который может быть использован при лечении головной боли, мигрени или гистаминовой головной боли.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46308903P | 2003-04-15 | 2003-04-15 | |
US60/463,089 | 2003-04-15 | ||
US51035203P | 2003-10-10 | 2003-10-10 | |
US60/510,352 | 2003-10-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2005135440A true RU2005135440A (ru) | 2006-03-20 |
RU2308458C2 RU2308458C2 (ru) | 2007-10-20 |
Family
ID=33303112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005135440/04A RU2308458C2 (ru) | 2003-04-15 | 2004-04-09 | Антагонисты рецептора cgrp |
Country Status (33)
Country | Link |
---|---|
US (6) | US6953790B2 (ru) |
EP (2) | EP1638969B1 (ru) |
JP (1) | JP3967766B2 (ru) |
KR (1) | KR100769030B1 (ru) |
CN (1) | CN100384843C (ru) |
AR (1) | AR045887A1 (ru) |
AT (1) | ATE413400T1 (ru) |
AU (1) | AU2004230926B2 (ru) |
BR (1) | BRPI0409601A (ru) |
CA (1) | CA2522220C (ru) |
CL (1) | CL2004000788A1 (ru) |
CO (1) | CO5640130A2 (ru) |
CY (1) | CY1108714T1 (ru) |
DE (1) | DE602004017608D1 (ru) |
DK (1) | DK1638969T3 (ru) |
EC (1) | ECSP056097A (ru) |
ES (1) | ES2314417T3 (ru) |
HK (1) | HK1090922A1 (ru) |
HR (1) | HRP20080666T3 (ru) |
IS (1) | IS2759B (ru) |
JO (1) | JO2355B1 (ru) |
MA (1) | MA27728A1 (ru) |
MX (1) | MXPA05011166A (ru) |
NO (1) | NO327655B1 (ru) |
NZ (1) | NZ543357A (ru) |
PE (1) | PE20050020A1 (ru) |
PL (1) | PL1638969T3 (ru) |
PT (1) | PT1638969E (ru) |
RU (1) | RU2308458C2 (ru) |
SI (1) | SI1638969T1 (ru) |
TW (1) | TWI314931B (ru) |
UA (1) | UA82877C2 (ru) |
WO (2) | WO2004092168A1 (ru) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
BRPI0311812B8 (pt) * | 2002-06-05 | 2021-05-25 | Bristol Myers Squibb Co | antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso |
US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
DE602004027021D1 (de) * | 2003-04-15 | 2010-06-17 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
GB0310881D0 (en) * | 2003-05-12 | 2003-06-18 | Merck Sharp & Dohme | Pharmaceutical formulation |
CA2529196A1 (en) * | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
US7196079B2 (en) * | 2003-06-26 | 2007-03-27 | Merck & Co, Inc. | Benzodiazepine CGRP receptor antagonists |
AR046787A1 (es) | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
CA2554351A1 (en) * | 2004-01-29 | 2005-08-11 | Merck & Co., Inc. | Cgrp receptor antagonists |
EP1732885A1 (en) * | 2004-02-23 | 2006-12-20 | Trustees Of Tufts College | Lactams as conformationally constrained peptidomimetic inhibitors |
TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
US7659264B2 (en) * | 2004-10-07 | 2010-02-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
CN101039718A (zh) | 2004-10-14 | 2007-09-19 | 默克公司 | Cgrp受体拮抗剂 |
US7745427B2 (en) | 2004-10-22 | 2010-06-29 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
GB2467060B (en) * | 2005-02-11 | 2010-09-01 | Cambridge Entpr Ltd | Ligands for G-protein coupled receptors |
GB2423085C (en) * | 2005-02-11 | 2011-11-09 | Cambridge Entpr Ltd | Ligands for G-protein coupled receptors |
CN101208303A (zh) * | 2005-03-14 | 2008-06-25 | 默克公司 | Cgrp受体拮抗剂 |
US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
EP3842458A1 (en) | 2005-11-14 | 2021-06-30 | Teva Pharmaceuticals International GmbH | Antagonist antibodies directed against calcitonin gene-related peptide |
CN100371327C (zh) * | 2005-11-17 | 2008-02-27 | 江苏工业学院 | 2-氨基-6-烷氧基-3-硝基吡啶的一步合成法 |
EP1954135B1 (en) * | 2005-11-18 | 2012-10-10 | Merck Sharp & Dohme Corp. | Spirolactam aryl cgrp receptor antagonists |
AU2007238896A1 (en) * | 2006-04-10 | 2007-10-25 | Merck Sharp & Dohme Corp. | CGRP antagonist salt |
ES2328186T3 (es) * | 2006-04-10 | 2009-11-10 | MERCK & CO., INC. | Procedimiento de preparacion de un intermedio de antagonista del cgrp de caprolactama. |
CA2649159A1 (en) | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Process for the preparation of cgrp antagonist |
WO2007120590A2 (en) * | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Process for the preparation of pyridine heterocycle cgrp antagonist intermediate |
US7470679B2 (en) | 2006-05-02 | 2008-12-30 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7470680B2 (en) * | 2006-05-03 | 2008-12-30 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
EP2024358B1 (en) * | 2006-05-09 | 2014-11-05 | Merck Sharp & Dohme Corp. | Substituted spirocyclic cgrp receptor antagonists |
MX2008015906A (es) * | 2006-06-13 | 2009-03-06 | Vertex Pharma | Antagonistas del receptor del peptido relacionado con el gen de calcitonina. |
US7834000B2 (en) * | 2006-06-13 | 2010-11-16 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
US8163737B2 (en) | 2006-06-13 | 2012-04-24 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
EP2995619B1 (en) * | 2006-08-02 | 2019-09-25 | Cytokinetics, Inc. | Certain chemical entities comprising imidazopyrimidines, compositions and methods |
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
CA2662748A1 (en) * | 2006-09-08 | 2008-03-13 | Merck & Co., Inc. | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
NZ580887A (en) | 2007-05-23 | 2012-03-30 | Merck Sharp & Dohme | Pyridyl piperidine orexin receptor antagonists |
GB0712392D0 (en) * | 2007-06-26 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
US20090075977A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched mk0974 |
JP2011511792A (ja) * | 2008-02-05 | 2011-04-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Cgrp受容体アンタゴニストのプロドラッグ |
CA2711367A1 (en) * | 2008-02-19 | 2009-08-27 | Merck Sharp & Dohme Corp. | Imidazobenzazepine cgrp receptor antagonists |
RU2522493C2 (ru) | 2008-03-04 | 2014-07-20 | Пфайзер Лимитед | Способы лечения хронической боли |
US8143403B2 (en) | 2008-04-11 | 2012-03-27 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8044043B2 (en) * | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
KR20110025926A (ko) * | 2008-06-30 | 2011-03-14 | 머크 샤프 앤드 돔 코포레이션 | 텔카게판트 칼륨의 고체 투여 제형 |
JP2012506379A (ja) * | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 二置換アゼパンオレキシン受容体アンタゴニスト |
US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
BR112012004464B8 (pt) | 2009-08-28 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica |
US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
TWI501968B (zh) | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑 |
CA2830348A1 (en) * | 2011-03-18 | 2012-09-27 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
US8748429B2 (en) | 2011-04-12 | 2014-06-10 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
EP2709663B1 (en) | 2011-05-20 | 2019-03-20 | AlderBio Holdings LLC | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
CA2836649C (en) | 2011-05-20 | 2020-06-23 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
BR112013029951B1 (pt) | 2011-05-20 | 2020-10-20 | Alderbio Holdings Llc | composição farmacêutica e uso de anticorpos ou fragmentos de anticorpos anti-cgrp para tratar ou prevenir formas de diarreia crônicas e agudas |
KR101951220B1 (ko) | 2011-07-13 | 2019-02-22 | 싸이토키네틱스, 인코포레이티드 | 조합 als 치료법 |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
EP2820016B1 (en) | 2012-02-27 | 2017-08-02 | Bristol-Myers Squibb Company | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b]pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b]pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt |
CN104203925A (zh) | 2012-03-29 | 2014-12-10 | 拜耳知识产权有限责任公司 | 5-氨基嘧啶衍生物及其用于防治不希望的植物生长的用途 |
CN105960397B (zh) | 2014-02-05 | 2020-09-04 | 默沙东公司 | Cgrp-活性化合物的片剂制剂 |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
KR20200126018A (ko) | 2014-03-21 | 2020-11-05 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법 |
GB201417707D0 (en) | 2014-10-07 | 2014-11-19 | Viral Ltd | Pharmaceutical compounds |
WO2017001434A1 (en) * | 2015-06-29 | 2017-01-05 | Galderma Research & Development | Cgrp receptor antagonist compounds for topical treatment of skin disorders |
GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
JP6937368B2 (ja) | 2016-09-23 | 2021-09-22 | テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー | 難治性片頭痛の治療方法 |
EP3366286A1 (en) | 2017-02-22 | 2018-08-29 | Johannes Keller | Compounds for treating sepsis |
GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
CA3087784A1 (en) | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
CN108892635A (zh) * | 2018-09-07 | 2018-11-27 | 江苏工程职业技术学院 | 一种西沙必利关键中间体的制备方法 |
SG11202106766SA (en) | 2019-01-08 | 2021-07-29 | H Lundbeck As | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
MX2023007575A (es) | 2020-12-22 | 2023-09-21 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
EP4301362A1 (en) | 2021-03-02 | 2024-01-10 | CGRP Diagnostics GmbH | Treatment and/or reduction of occurrence of migraine |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
WO1996035713A1 (en) | 1995-05-08 | 1996-11-14 | Pfizer, Inc. | Dipeptides which promote release of growth hormone |
CN1117091C (zh) | 1998-09-30 | 2003-08-06 | 大正制药株式会社 | 取代的异噁唑基噻吩化合物 |
EP1117662A1 (en) * | 1998-09-30 | 2001-07-25 | Merck Sharp & Dohme Limited | Benzimidazolinyl piperidines as cgrp ligands |
BRPI0311812B8 (pt) * | 2002-06-05 | 2021-05-25 | Bristol Myers Squibb Co | antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso |
DE602004027021D1 (de) * | 2003-04-15 | 2010-06-17 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
-
2004
- 2004-04-07 JO JO200445A patent/JO2355B1/en active
- 2004-04-09 JP JP2006509818A patent/JP3967766B2/ja not_active Expired - Fee Related
- 2004-04-09 PL PL04749887T patent/PL1638969T3/pl unknown
- 2004-04-09 RU RU2005135440/04A patent/RU2308458C2/ru not_active IP Right Cessation
- 2004-04-09 EP EP04749887A patent/EP1638969B1/en not_active Expired - Lifetime
- 2004-04-09 PT PT04749887T patent/PT1638969E/pt unknown
- 2004-04-09 CN CNB2004800161154A patent/CN100384843C/zh not_active Expired - Fee Related
- 2004-04-09 MX MXPA05011166A patent/MXPA05011166A/es active IP Right Grant
- 2004-04-09 CA CA002522220A patent/CA2522220C/en not_active Expired - Fee Related
- 2004-04-09 WO PCT/US2004/011280 patent/WO2004092168A1/en active Application Filing
- 2004-04-09 KR KR1020057019692A patent/KR100769030B1/ko not_active IP Right Cessation
- 2004-04-09 SI SI200430961T patent/SI1638969T1/sl unknown
- 2004-04-09 NZ NZ543357A patent/NZ543357A/en not_active IP Right Cessation
- 2004-04-09 AT AT04749887T patent/ATE413400T1/de active
- 2004-04-09 AU AU2004230926A patent/AU2004230926B2/en not_active Ceased
- 2004-04-09 EP EP08105721.8A patent/EP2039694B1/en not_active Expired - Lifetime
- 2004-04-09 ES ES04749887T patent/ES2314417T3/es not_active Expired - Lifetime
- 2004-04-09 DE DE602004017608T patent/DE602004017608D1/de not_active Expired - Lifetime
- 2004-04-09 DK DK04749887T patent/DK1638969T3/da active
- 2004-04-09 WO PCT/US2004/010851 patent/WO2004092166A2/en active Application Filing
- 2004-04-09 BR BRPI0409601-0A patent/BRPI0409601A/pt not_active IP Right Cessation
- 2004-04-12 PE PE2004000364A patent/PE20050020A1/es not_active Application Discontinuation
- 2004-04-13 AR ARP040101238A patent/AR045887A1/es active IP Right Grant
- 2004-04-13 CL CL200400788A patent/CL2004000788A1/es unknown
- 2004-04-14 TW TW093110393A patent/TWI314931B/zh not_active IP Right Cessation
- 2004-05-04 US US10/838,835 patent/US6953790B2/en not_active Expired - Lifetime
- 2004-09-04 UA UAA200510685A patent/UA82877C2/uk unknown
-
2005
- 2005-06-14 US US11/152,537 patent/US7235545B2/en active Active
- 2005-09-29 IS IS8055A patent/IS2759B/is unknown
- 2005-10-11 MA MA28550A patent/MA27728A1/fr unknown
- 2005-10-12 EC EC2005006097A patent/ECSP056097A/es unknown
- 2005-10-12 CO CO05104372A patent/CO5640130A2/es active IP Right Grant
- 2005-11-14 NO NO20055375A patent/NO327655B1/no not_active IP Right Cessation
-
2006
- 2006-10-20 HK HK06111605.8A patent/HK1090922A1/xx not_active IP Right Cessation
-
2007
- 2007-03-14 US US11/724,066 patent/US7452903B2/en not_active Expired - Lifetime
-
2008
- 2008-04-09 US US12/082,233 patent/US7534784B2/en not_active Expired - Lifetime
- 2008-12-19 HR HR20080666T patent/HRP20080666T3/xx unknown
-
2009
- 2009-01-15 CY CY20091100053T patent/CY1108714T1/el unknown
- 2009-04-03 US US12/417,911 patent/US7772224B2/en not_active Expired - Lifetime
-
2010
- 2010-07-07 US US12/831,802 patent/US7893052B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005135440A (ru) | Антагонисты рецептора cgrp | |
CA2522024A1 (en) | Cgrp receptor antagonists | |
RU2310648C2 (ru) | 5-замещенные пиразиновые или пиридиновые активаторы глюкокиназы | |
AU2009330686B2 (en) | Compounds for the treatment of cancer | |
RU2417226C2 (ru) | Производные азаиндол-2-карбоксамида | |
JP2006517220A5 (ru) | ||
PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
PE20011334A1 (es) | Compuestos y composiciones de indazol de formula (i) | |
RU2014153627A (ru) | Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ | |
AR057848A1 (es) | Diarilureas para el tratamiento de la hipertension pulmonar | |
RU2430923C2 (ru) | Тиазолилдигидрохиназолины | |
CO4940472A1 (es) | Pirazolopirimidonas para la disfuncion sexual | |
JP2005535586A5 (ru) | ||
RU2010126105A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства | |
AR057106A2 (es) | USO DE COMPUESTOS DERIVADOS DE PIPERAZINA UTILES COMO ANTAGONISTAS CCR5, PARA LA PREPARACIoN DE MEDICAMENTOS | |
RU2008126391A (ru) | Производные 1,5-замещенного индол-2-иламида | |
PE20090477A1 (es) | Derivados de oxazol como inhibidores de los canales de sodio | |
RU2004122414A (ru) | Цис-2,4,5-трифенилимидазолины и их применение для лечения опухолевых заболеваний | |
JP2005538100A5 (ru) | ||
HK1110868A1 (en) | Heterocyclic compounds as ccr2b antagonists | |
RU2006128788A (ru) | Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов | |
JP2010513322A5 (ru) | ||
PE20080405A1 (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb | |
PE20070212A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
PE20070359A1 (es) | Inhibidores de pirimidinilpirazol de aurora quinasas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Correction of name of patent owner | ||
PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20130530 |
|
PD4A | Correction of name of patent owner | ||
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140410 |